Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Premature ovarian insufficiency, Irregular menstruation, Female infertility, and Elevated circulating follicle stimulating hormone level and others. 6 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Blood and immune system | 1 | Autoimmunity |
SPATA22 function has not been fully characterized.
Premature ovarian failure 25 is associated with mutations in the SPATA22 gene on chromosome 17.
Genetic testing for SPATA22 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for premature ovarian failure 25 has been reported in the published literature.
Phenotype severity distribution: 5 always present features.
No clinical trials have been registered for premature ovarian failure 25.
93 publications have been identified in PubMed for premature ovarian failure 25. Research spans Epidemiology / Natural History (43%), Review / Meta-Analysis (27%), and Basic Science / Preclinical (15%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 40 | 43% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 6:56 PM UTC
Online Mendelian Inheritance in Man
1 |
Female infertility |
Lab test results | 1 | Elevated circulating follicle stimulating hormone level |
Research summaries
25 |
27% |
Laboratory research | 14 | 15% |
Clinical study results | 6 | 6% |
Testing and diagnosis research | 3 | 3% |
Patient case studies | 2 | 2% |
New treatment approaches | 2 | 2% |
Other research | 1 | 1% |
Grandi G (2026). [PMID: 42132994](https://pubmed.ncbi.nlm.nih.gov/42132994/). *Fam Cancer*. [Epidemiology / Natural History]
Sonmezer M (2026). [PMID: 41206517](https://pubmed.ncbi.nlm.nih.gov/41206517/). *Hum Reprod Update*. [Review / Meta-Analysis]
Tanaka S (2026). [PMID: 42024254](https://pubmed.ncbi.nlm.nih.gov/42024254/). *Int Orthop*. [Clinical Trial Publication]
Zhang Q (2026). [PMID: 41947243](https://pubmed.ncbi.nlm.nih.gov/41947243/). *Stem Cell Res Ther*. [Basic Science / Preclinical]
Capozzi A (2026). [PMID: 41212137](https://pubmed.ncbi.nlm.nih.gov/41212137/). *Minerva Endocrinol (Torino)*. [Review / Meta-Analysis]
Dyre LJ (2026). [PMID: 42228436](https://pubmed.ncbi.nlm.nih.gov/42228436/). *Menopause*. [Epidemiology / Natural History]
Malick SM (2026). [PMID: 41556851](https://pubmed.ncbi.nlm.nih.gov/41556851/). *Menopause*. [Clinical Trial Publication]
Guo M (2026). [PMID: 41722334](https://pubmed.ncbi.nlm.nih.gov/41722334/). *Maturitas*. [Epidemiology / Natural History]
Chen JH (2026). [PMID: 41640848](https://pubmed.ncbi.nlm.nih.gov/41640848/). *Front Public Health*. [Epidemiology / Natural History]
Gootzen TA (2026). [PMID: 41955317](https://pubmed.ncbi.nlm.nih.gov/41955317/). *J Natl Cancer Inst*. [Epidemiology / Natural History]